Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.65 |
| ▸ | CES1 | P23141 | 1/20 | 0.65 |
| ▸ | PARP1 | P09874 | 1/20 | 0.61 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.60 |
| ▸ | CHRNG | P07510 | 1/20 | 0.60 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.60 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.60 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.60 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
| ▸ | CHRND | Q07001 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15007434 | 1.00 | CES2 (0.65) | CES2CES1PARP1CHRNA1CHRNG | |
| SCHEMBL5218170 | 0.87 | CES2 (0.67) | CES2CES1PARP1CHRNA1CHRNG | |
| SCHEMBL1164163 | 0.87 | CES2 (0.67) | CES2CES1PARP1CHRNA1CHRNG | |
| SCHEMBL7427631 | 0.87 | CES2 (0.67) | CES2CES1PARP1CHRNA1CHRNG | |
| SCHEMBL14490225 | 0.86 | KMT2A (0.56) | CES2CES1PARP1CHRNA1CHRNG | |
| SCHEMBL5175691 | 0.86 | KMT2A (0.56) | CES2CES1PARP1CHRNA1CHRNG | |
| SCHEMBL20090393 | 0.86 | CES2 (0.65) | CES2CES1PARP1CHRNA1CHRNG | |
| SCHEMBL1358606 | 0.84 | CES2 (0.62) | CES2CES1PARP1CHRNA1CHRNG | |
| SCHEMBL9366959 | 0.84 | CES2 (0.62) | CES2CES1PARP1CHRNA1CHRNG | |
| SCHEMBL8992548 | 0.84 | PARP1 (0.64) | CES2CES1PARP1CHRNA1CHRNG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112574048-A | Butoxymin hydrochloride and preparation method thereof | 广东嘉博制药有限公司 | 2021-03-30 | — | — | CN | claimed |
| CN-112759510-A | Preparation method of methoxamine hydrochloride degradation impurities | 广东嘉博制药有限公司 | 2021-05-07 | — | — | CN | disclosed |
| CN-112574048-A | Butoxymin hydrochloride and preparation method thereof | 广东嘉博制药有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-112574048-A | Butoxymin hydrochloride and preparation method thereof | 广东嘉博制药有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-112266322-A | Method for removing and recovering impurities in reaction raw materials for synthesizing methoxamine hydrochloride | 广东嘉博制药有限公司 | 2021-01-26 | — | — | CN | disclosed |
| CN-108083999-B | Green preparation method of alpha-hydroxyketone | 西北师范大学 | 2020-08-11 | — | — | CN | disclosed |
| US-9527823-B2 | Hydroxybupropion analogues for treating drug dependence | RESEARCH TRIANGLE INSTITUTE (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2571859-B1 | 1-PHENYLMORPHOLINE DERIVATIVES AS HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE | RES TRIANGLE INST (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20150141416-A1 | HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE | RESEARCH TRIANGLE INSTITUTE | 2015-05-21 | — | — | US | disclosed |
| US-8906908-B2 | Hydroxybupropion analogues for treating drug dependence | RESEARCH TRIANGLE INSTITUTE (US) | 2014-12-09 | — | — | US | disclosed |
| US-20130150357-A1 | HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE | RESEARCH TRIANGLE INSTITUTE (US) | 2013-06-13 | — | — | US | disclosed |
| EP-2571859-A2 | HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE | Research Triangle Institute (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011146821-A2 | 1 - PHENYLMORPHOLINE DERIVATIVES AS HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE | RESEARCH TRIANGLE INSTITUTE (US) | 2011-11-24 | — | — | WO | disclosed |
| EP-1048737-B1 | Stereoselective synthesis of 2-hydroxycétones | FORSCHUNGSZENTRUM JUELICH GMBH (DE) | 2007-06-06 | — | — | EP | disclosed |
| EP-0771794-B1 | OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO KK (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-6716987-B1 | PHOSPHODIESTERASE IV INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-04-06 | — | — | US | disclosed |
| US-6514996-B2 | Derivatives of benzofuran or benzodioxole | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-02-04 | — | — | US | disclosed |
| US-20020128290-A1 | DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-09-12 | — | — | US | disclosed |
| EP-0771794-A1 | OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128290-A1 | DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE | CBR1, CBR3, CYC1 | CES2 540/4885CES1 216/4885PARP1 1423/4885 |
| US-20130150357-A1 | HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE | SLC6A2, SLC6A3, HTR3B | CES2 91/4885CES1 333/4885PARP1 2948/4885 |
| US-20150141416-A1 | HYDROXYBUPROPION ANALOGUES FOR TREATING DRUG DEPENDENCE | SLC6A2, SLC6A3, HTR3B | CES2 91/4885CES1 333/4885PARP1 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.